Stock market analyst Kunal Saraogi has maintained 'buy' rating on Orchid Chemicals & Pharmaceuticals Limited stock with a target of Rs 210.

According to analyst, the interested investors can buy the stock with stop loss of Rs 184.

The stock of the company, on Sep 16, closed at Rs 188.55 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 239.40 and a low of Rs 128 on BSE.

Current EPS is -76.52.

K. Raghavendra Rao-led promoter group increased its equity stake in the company (Orchid Chemicals) to 31% as against 26% by purchasing a big part of the shares from the Ranbaxy Group.

It should be remembered that Ranbaxy Group created quite a stir when it purchased around 14% scrips in Orchid in the open market, cashing in on the havoc actuated by the sale of Orchid scrips by international investor Bear Sterns during the first half of the year 2008.

Bear Sterns held around a million scrips in Orchid.

Set up in the year 1992, Orchid has attained incredible and steady growth, quantitatively and qualitatively to come out as the Top-15 firms in the country's pharma biz in a short span.

The company employs more than 4000 people, out of which around 700 are researchers, engineers and other experts.